CorMedix Inc. CRMD revenue by segment, product and geography
In its fiscal year ending 2025-12-31, CorMedix Inc. reported revenue across 4 products and services; the largest, Product, was $304M (+600.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$304Mshare n/a+600.1% yoy
- Defen Cath$259Mshare n/a+495.4% yoy
- Melinta Portfolio$45.5Mshare n/ano prior
- Contract Revenue$7.37Mshare n/ano prior
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Product$122Mshare n/a+211.9% yoy
- Defen Cath$97.5Mshare n/a+149.5% yoy
- Melinta Portfolio$24.4Mshare n/ano prior
- Contract Revenue$5.51Mshare n/ano prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.